NEW YORK (GenomeWeb News) – Veridex announced this week a deal with Laboratory Corporation of America to make its CellSearch circulating tumor cell test available in China.

LabCorp's Beijing central laboratory is now the first clinical reference laboratory in the country to offer CTC testing and will offer the test to researchers conducting clinical trials.

The agreement follows regulatory approval in China last month for the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.